Alexion Pharmaceuticals Inc. Release: Early Clinical Experience and Basic Science Support Further Investigation of Soliris(R) (eculizumab) for the Treatment of Patients with Thrombotic Microangiopathy

CHESHIRE, Conn.--(BUSINESS WIRE)--Researchers reported today that Soliris® (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), may provide clinical benefits to patients with thrombotic microangiopathy (TMA) resulting from uncontrolled complement activation. TMA, the formation of blood clots in capillaries and small arteries, can lead to life-threatening damage in multiple organs including kidney failure, thrombocytopenia (abnormally low platelet count) and anemia.